SK Biopharmaceuticals: Seizures trials

The registry lists 16 Seizures studies with SK Biopharmaceuticals as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 1Phase 3 13Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsRecruitingNCT05219617Phase 3
• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC SeizuresCompletedNCT03678753Phase 3Results posted
• Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedNCT02535091Phase 3Results posted
• Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresCompletedNCT01397968Phase 2Results posted
• Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyActive, not recruitingNCT06453213Phase 4
• Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresCompletedNCT05067634Phase 3
• Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset SeizuresCompletedNCT04903314Phase 1
• Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POSCompletedNCT04557085Phase 3
• An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.CompletedNCT00991757Phase 3
• An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset SeizuresCompletedNCT00744731Phase 3
• A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.CompletedNCT00740623Phase 3
• Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresCompletedNCT00697918Phase 3
• Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresTerminatedNCT00697762Phase 3
• Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.TerminatedNCT00563459Phase 3
• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00433667Phase 3
• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00425282Phase 3